44.2 F
New York
Friday, December 9, 2022

Date:

Share:

Biomed Industries, Inc. Comments on Roche’s Alzheimer’s Phase III Trial

Related Articles

Gail Louise Dempsey’s New Book, “Day 7,” Follows Victor, Who Experiences a Low White Blood Cell (WBC) Count After Chemo and Receives Medication to...

Greensboro, NC, December 09, 2022 --(PR.com)-- Fulton Books author Gail Louise Dempsey, who has her doctorate in chemical engineering and works in drug development, has...

Author Fitzroy (Smitty) Smith’s New Audiobook, “My Prince,” is a Heartfelt & Personal Account of the Difficult Moment in the Author’s Life When He...

Jamaica, NY, December 09, 2022 --(PR.com)-- Fitzroy (Smitty) Smith, an author and father, has completed his new audiobook, “My Prince”: a heartbreaking account of the...

Thrombolex Announces Publication in the Journal of the American College of Cardiology, Cardiovascular Interventions

New Britain, PA, December 08, 2022 --(PR.com)-- Thrombolex, Inc., a medical device company focused on developing innovative products for the treatment of arterial and venous...
San Jose, CA, November 19, 2022 –(PR.com)– In a news release dated November 14, 2022, Roche announced that their Alzheimer’s drug candidate, gantenerumab, did not perform meaningfully better than a placebo. About 25% of all patients who received gantenerumab were also associated with higher rates of an imaging abnormality that can involve swelling or bleeding in the brain.

“The quest to develop an Alzheimer’s drug by targeting beta-amyloid has been beset by a long list of clinical trials failures,” stated Dr. Zung Vu Tran, Vice President of Bioinformatics & AI for Biomed Industries and Chief Science Officer at MedAware Systems, Inc. He added: “While this is discouraging news for the many patients and families living with Alzheimer’s, other promising methods and new therapies for Alzheimer’s patients are in development.”

Biomed’s NA-831 drug is a novel treatment for Alzheimer’s disease that takes a different…

Read more…

Popular Articles